AgomAb Therapeutics NV (AGMB) Cash Flow Statement
Where AGMB’s cash came from and went, 2025
December 31, 2025 · euros- Cash from operations
- −€51.7M
- Capital expenditures
- €4,000
- Free cash flow
- −€51.7M
- Returned to shareholders
- —
- Change in cash
- −€85.0M cash at year-end €86.4M
Drawn to scale: where the cash came from and how it was used. Hover for values.
AGMB operating cash flow, capex and free cash flow
AGMB cash flow trends, 2022–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −€19.0M2022 | −€51.7M2025 | — | |
| Capital expenditures | €02022 | €4,0002025 | — | |
| Free cash flow | −€19.0M2022 | −€51.7M2025 | — | |
| Stock-based compensation | €2.2M2022 | €5.4M2025 | +34.3%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
AGMB cash flow by activity
AGMB net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
AGMB cash flow statement in euros
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating activities | ||||
| Net income | −€62.5M | −€46.3M | −€11.4M | −€8.1M |
| Depreciation & amortization | €219,000 | €311,000 | €99,000 | €23,000 |
| Stock-based compensation | €5.4M | €1.1M | €2.2M | €2.2M |
| Change in working capital | €406,000 | −€1.3M | €4.1M | €1.4M |
| Other non-cash items | €4.8M | −€661,000 | −€19.6M | −€14.5M |
| Cash from operating activities | −€51.7M | −€46.8M | −€24.6M | −€19.0M |
| Investing activities | ||||
| Capital expenditures | −€4,000 | −€675,000 | €0 | €0 |
| Investments (net) | −€30.0M | €0 | €40.0M | −€40.0M |
| Acquisitions & other investing | −€3.0M | — | — | — |
| Cash from investing activities | −€33.0M | — | — | — |
| Financing activities | ||||
| Net borrowing (repayment) | −€338,000 | −€163,000 | −€100,000 | −€717,000 |
| Shares issued | €0 | €97.1M | €79.9M | €38.4M |
| Other financing | €0 | −€129,000 | −€447,000 | −€36,000 |
| Cash from financing activities | −€338,000 | €96.8M | €79.3M | €37.6M |
| Summary | ||||
| Net change in cash | −€85.0M | €49.3M | €94.7M | −€25.9M |
| Cash at end of period | €86.4M | €171.5M | €122.4M | €27.7M |
| Free cash flow | −€51.7M | −€47.5M | −€24.6M | −€19.0M |
| Mar '26 | Dec '25 | Sep '25 | Dec '24 | |
|---|---|---|---|---|
| Operating activities | ||||
| Net income | −€11.7M | −€17.4M | −€18.3M | −€11.7M |
| Depreciation & amortization | €85,000 | −€83,000 | €107,000 | €85,000 |
| Stock-based compensation | €499,000 | €1.4M | €1.3M | €499,000 |
| Change in working capital | −€1.6M | €1.4M | €127,000 | −€1.6M |
| Other non-cash items | €333,000 | €1.5M | €3.1M | €333,000 |
| Cash from operating activities | −€12.4M | −€13.2M | −€13.6M | −€12.4M |
| Investing activities | ||||
| Capital expenditures | −€363,000 | −€4,000 | €0 | −€363,000 |
| Acquisitions & other investing | €0 | −€30.0M | — | €0 |
| Cash from investing activities | −€363,000 | −€30.0M | — | −€363,000 |
| Financing activities | ||||
| Net borrowing (repayment) | — | −€34,000 | −€156,000 | −€63,000 |
| Shares issued | €0 | €0 | €0 | €82.1M |
| Other financing | €81.9M | €0 | €0 | −€130,000 |
| Cash from financing activities | €81.9M | −€34,000 | −€156,000 | €81.9M |
| Summary | ||||
| Net change in cash | €68.9M | −€43.2M | −€13.8M | €68.9M |
| Cash at end of period | €171.5M | €86.4M | €129.6M | €171.5M |
| Free cash flow | −€12.8M | −€13.2M | −€13.6M | −€12.8M |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in euros as reported; data from EODHD.
AGMB cash generation
In fiscal 2025 (ended December 31, 2025), AgomAb Therapeutics NV generated -€51.7 million of cash from operations and spent €0.0 million on capital expenditures, leaving free cash flow of -€51.7 million. Cash and equivalents fell by €85.0 million over the year.
Related: AGMB income statement, AGMB balance sheet. See the AGMB stock overview for the latest quote and news.
AGMB cash flow FAQ
What is AgomAb Therapeutics NV's free cash flow?
AgomAb Therapeutics NV's free cash flow was -€51.7 million in fiscal 2025: -€51.7 million of operating cash flow minus €0.0 million of capital expenditures It was -€47.5 million a year earlier..
How much cash does AgomAb Therapeutics NV generate from operations?
AgomAb Therapeutics NV generated -€51.7 million of cash from operating activities in fiscal 2025.
How much does AgomAb Therapeutics NV spend on capital expenditures?
AgomAb Therapeutics NV spent €0.0 million on capital expenditures in fiscal 2025, compared with €0.7 million the year before.